Lakefront Biotherapeutics (LKFT) Other financing activities (2014 - 2017)
Lakefront Biotherapeutics (LKFT) posted quarterly Other financing activities of $9.4 million for Q4 2017, up 100.1% on a QoQ basis from -$9.4 billion in Q3 2017.
Lakefront Biotherapeutics (LKFT) Other financing activities (2014 - 2017) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Other financing activities for 2 consecutive years, with $9.4 million the latest figure, recorded in Q4 2017.
- Quarterly Other financing activities changed N/A year-over-year to $9.4 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $18.7 million (changed N/A YoY) and the FY2017 annual result came in at $9.4 million, up 2679.15% from the prior year.
- Other financing activities rose to $9.4 million in Q4 2017 per LKFT's latest filing, from -$9.4 billion in the prior quarter.
- Over the last five years, Other financing activities for LKFT reached as high as $9.4 billion in Q2 2017 and fell as low as -$9.4 billion in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 9.43 Mn |
| Dec 31, 2017 | 9.43 Mn |
| Sep 30, 2017 | -9.42 Bn |
| Sep 30, 2017 | -9.42 Bn |
| Jun 30, 2017 | 9.42 Bn |
| Jun 30, 2017 | 9.42 Bn |
| Mar 31, 2017 | 9.43 Mn |
| Mar 31, 2017 | 9.43 Mn |
| Dec 31, 2014 | -10.71 Mn |
| Dec 31, 2014 | -10.71 Mn |